Harmonic Partners with Evolution Digital to Simplify Fiber Broadband Deployments
Collaboration Strengthens Harmonic's Open ONU Vision, Driving Down Fiber Broadband Deployment Costs
SAN JOSE, Calif., May 13, 2025 /PRNewswire/ -- Harmonic (NASDAQ: HLIT) today announced a new partnership with Evolution Digital, a global leader in advanced connectivity solutions, further expanding its roster of interoperable ONU partners and reinforcing the company's commitment to creating an open, flexible fiber broadband ecosystem. This powerful collaboration strengthens Harmonic's mission to empower broadband operators through its Open ONU approach that eliminates vendor lock-in and reduces fiber deployment costs.
Harmonic's cOS™ virtualized broadband platform offers seamless interoperability with Evolution Digital's EVO1111XG XGS-PON bridge and EVO6022GP3 integrated Wi-Fi 6 GPON gateway. Integration efforts between the two companies will support additional GPON and XGS-PON devices in the near future.
'We're excited that our ongoing collaboration has led to our inclusion in Harmonic's Open ONU initiative, which reflects a scalable and forward-thinking strategy to support the unique business needs of the global broadband provider community,' said Marc Cohen, chief revenue officer at Evolution Digital. 'Our interoperability with Harmonic's virtualized broadband platform — including support for GPON and 10G-capable fiber-to-the-home devices — enables partners to accelerate deployments and deliver high-quality fiber services more efficiently.'
Harmonic's cOS virtualized core software allows operators to support ONU devices from any vendor, now including Evolution Digital. This expanded interoperability empowers broadband providers to choose a CPE that best fits their performance, cost and deployment requirements. As a result, operators can accelerate fiber service rollouts, lower capital expenditures and deliver high-speed connectivity to more subscribers.
'The momentum around ONU interoperability is transforming how operators build and scale their fiber networks,' said Hy Huynh, vice president of fiber products at Harmonic. 'With the addition of Evolution Digital to our growing list of certified ONU partners, we're giving operators more choice and flexibility to deliver high-speed connectivity with unmatched cost efficiency.'
Harmonic will demonstrate its fiber broadband solutions at Fiber Connect 2025, June 1-4 in Nashville, in booth 824.
Harmonic's market-leading cOS platform powers next-gen broadband services to more than 33 million homes worldwide for leading operators in North America, Europe, Latin America and Asia. To learn more about the cOS platform and range of fiber solutions, visit www.harmonicinc.com/broadband.
About Harmonic
Harmonic (NASDAQ: HLIT), the worldwide leader in virtualized broadband and video delivery solutions, enables media companies and service providers to deliver ultra-high-quality video streaming and broadcast services to consumers globally. The company revolutionized broadband networking via the industry's first virtualized broadband solution, enabling operators to more flexibly deploy gigabit internet services to consumers' homes and mobile devices. Whether simplifying OTT video delivery via innovative cloud and software platforms, or powering the delivery of gigabit internet services, Harmonic is changing the way media companies and service providers monetize live and on-demand content on every screen. More information is available at www.harmonicinc.com.
Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements concerning Harmonic's business and the anticipated capabilities, advantages, reliability, efficiency, market acceptance, market growth, specifications and benefits of Harmonic products, services and technology are forward-looking statements. These statements are based on our current expectations and beliefs and are subject to risks and uncertainties, including the risks and uncertainties more fully described in Harmonic's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended Dec. 31, 2024, its Quarterly Reports on Form 10-Q and its Current Reports on Form 8-K. The forward-looking statements in this press release are based on information available to Harmonic as of the date hereof, and Harmonic disclaims any obligation to update any forward-looking statements.
Harmonic, the Harmonic logo and other Harmonic marks are owned by Harmonic Inc. or its affiliates. All other trademarks referenced herein are the property of their respective owners.
About Evolution Digital
Evolution Digital L.L.C. is a leading provider of a comprehensive suite of integrated video streaming, whole-home Wi-Fi and advanced connectivity products for the global market. We partner with ISPs to deliver reliable, high-performance technologies that enhance their subscribers' connected lifestyles. We take an aggressive approach to product innovation to embrace new technologies that require high-performance, reliable and user-friendly solutions. Learn more at www.evolutiondigital.com.
Photo Link: www.202comms.com/Harmonic/Harmonic-cOS_logo.jpg
Photo Caption: Harmonic cOS™ Broadband Platform Logo
Photo Link: www.202comms.com/Harmonic/Harmonic-evo.png
Photo Caption: Evolution Digital EVO1111XG XGS-PON 10G Bridge
View original content to download multimedia: https://www.prnewswire.com/news-releases/harmonic-partners-with-evolution-digital-to-simplify-fiber-broadband-deployments-302453482.html
SOURCE Harmonic Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
an hour ago
- Business Upturn
Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer
By GlobeNewswire Published on June 2, 2025, 10:15 IST Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant and clinically meaningful benefit for Pluvicto™ plus hormone therapy versus hormone therapy alone, with positive trend in overall survival (OS) 1 Pluvicto is already approved for metastatic castration-resistant prostate cancer (mCRPC) and now shows potential in patients in an earlier disease setting 1,2 Novartis to present results at an upcoming medical meeting and, based on FDA feedback, will submit for regulatory review in the second half of the year Novartis is investigating a broad portfolio of RLTs in advanced cancers, including breast, colon, lung and pancreatic and is investing in multiple manufacturing facilities, with industry-leading infrastructure to accelerate delivery of RLTs to patients Basel, June 2, 2025 – Novartis today announced topline results from a pre-specified interim analysis of the Phase III PSMAddition trial. The trial met its primary endpoint with a statistically significant and clinically meaningful benefit in radiographic progression-free survival (rPFS) with a positive trend in overall survival (OS) in patients with prostate-specific membrane antigen (PSMA)-positive metastatic hormone-sensitive prostate cancer (mHSPC) treated with radioligand therapy (RLT), Pluvicto™ (lutetium (177Lu) vipivotide tetraxetan), in combination with standard of care (SoC) versus SoC alone1. In PSMAddition, the SoC is a combination of androgen receptor pathway inhibitor (ARPI) therapy and androgen deprivation therapy (ADT)3. Almost all mHSPC patients ultimately progress to metastatic castration-resistant prostate cancer (mCRPC)4. There is a need for additional treatment options with novel mechanisms of action that further delay progression, prolong OS and improve disease control compared to the current SoC, while showing a favorable safety and tolerability profile. 'The progression from metastatic hormone-sensitive prostate cancer to castration-resistant disease remains a formidable challenge that can profoundly impact the survival of patients,' said Shreeram Aradhye, M.D., President, Development and Chief Medical Officer at Novartis. 'These results further strengthen our confidence in Pluvicto as a PSMA-targeted radioligand therapy. Following the recent FDA approval based on the PSMAfore trial in metastatic castration-resistant prostate cancer, these data suggest using it in an earlier disease setting could advance care and address a significant unmet need for hormone-sensitive prostate cancer patients.' This is the third positive read-out for Pluvicto in a Phase III trial, following the VISION and PSMAfore studies5,6. Results from PSMAddition in mHSPC show potential for treatment in an earlier setting with Pluvicto, which was recently granted US Food and Drug Administration (FDA) approval for earlier use in mCRPC, based on results from PSMAfore1,2. Novartis is harnessing the innovation of world-class scientists, strategic partnerships and one of the industry's most competitive pipelines to explore the potential of new, targeted therapies and precision medicine platforms to address the greatest unmet needs in prostate cancer. Data will be presented at an upcoming medical meeting and, based on FDA feedback, will be submitted for regulatory review in the second half of the year. About PSMAddition study PSMAddition (NCT04720157) is a Phase III, open-label, prospective, 1:1 randomized study comparing the efficacy and safety of Pluvicto in combination with SoC (ARPI + ADT) vs. SoC alone in adult patients with PSMA-positive mHSPC3. Patients randomized to the SoC alone arm are allowed to crossover to receive Pluvicto, upon confirmation of radiographic progression by blinded independent review committee (BIRC) and per the discretion of the treating physician3. The primary endpoint is rPFS, defined as the time to radiographic progression by PCWG3-modified RECIST V1.1 (as assessed by BIRC) or death3. The key secondary endpoint of OS is defined as time to death due to any cause3. About Pluvicto™ (INN: lutetium (177Lu) vipivotide tetraxetan) Pluvicto is an intravenous RLT that combines a targeting compound (a ligand) with a therapeutic radionuclide (a radioactive particle, in this case lutetium-177)5,7. After administration into the bloodstream, Pluvicto binds to PSMA-expressing target cells, including prostate cancer cells that express PSMA, a transmembrane protein5,7. Once bound, energy emissions from the radioisotope damage the target cells and nearby cells, disrupting their ability to replicate and/or triggering cell death7. Pluvicto is the only PSMA-targeted agent approved for PSMA-positive mCRPC and is the first targeted RLT to demonstrate a clinical benefit for patients with PSMA-positive mHSPC1. Novartis is investigating Pluvicto in earlier stages of disease, including oligometastatic prostate cancer (PSMA-DC, NCT05939414). Novartis and radioligand therapy (RLT) Novartis is reimagining cancer care with RLT for patients with advanced cancers. By harnessing the power of targeted radiation and applying it to advanced cancers, RLT is designed to deliver treatment directly to target cells, anywhere in the body8,9. Novartis is investigating a broad portfolio of RLTs, exploring new isotopes, ligands and combination therapies to look beyond gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and prostate cancer and into breast, colon, lung and pancreatic cancer. Novartis has established global expertise, with specialized supply chain and manufacturing capabilities across its network of RLT production sites. To support growing demand for RLTs, we have expanded production capabilities in Millburn (NJ), Zaragoza (Spain), Ivrea (Italy) and a state-of-the-art facility in Indianapolis (IN). In Carlsbad (CA), Novartis is establishing its third US-based RLT manufacturing site to support expanded use of RLTs, create resiliency in its manufacturing network and optimize the delivery of medicines to patients on the West Coast. Disclaimer This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as 'potential,' 'can,' 'will,' 'may,' 'could,' 'trend,' 'potentially,' 'upcoming,' 'progression,' 'progress,' 'investigating,' 'investing,' 'look beyond,' or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for Pluvicto, or regarding potential future revenues from Pluvicto. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that Pluvicto will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that Pluvicto will be commercially successful in the future. In particular, our expectations regarding Pluvicto could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. About Novartis Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide. Reimagine medicine with us: Visit us at and connect with us on LinkedIn, Facebook, X/Twitter and Instagram. References Data on file. Pluvicto [prescribing information]. Millburn, NJ: Advanced Accelerator Applications USA, Inc.; 2025. An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC (PSMAddition). identifier: NCT04720157. Updated March 5, 2025. Accessed June 2, 2025. Oing C, Bristow RG. Systemic treatment of metastatic hormone-sensitive prostate cancer—upfront triplet versus doublet combination therapy. ESMO Open 2023l doi: 10.1016/ Sartor O, J. de Bono KN, Chi K, et al. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. NEJM 2021; doi: 10.1056/NEJMoa2107322. Morris M, Castellano D, Herrmann K, et al. 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. The Lancet 2024; doi: 10.1016/S0140-6736(24)01653-2. University of Chicago Medicine. Lutetium-177 PSMA Therapy for Prostate Cancer (Pluvicto). Accessed June 18, 2024. Jadvar H. Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment [published correction appears in AJR Am J Roentgenol. 2017 Oct;209(4):949. doi: 10.2214/AJR.17.18875]. AJR Am J Roentgenol. 2017;209(2):277-288. doi:10.2214/AJR.17.18264 Jurcic JG, Wong JYC, Knoc SJ, et al. Targeted radionuclide therapy. In: Tepper JE, Foote RE, Michalski JM, eds. Gunderson & Tepper's Clinical Radiation Oncology. 5th ed. Elsevier, Inc. 2021;71(3):209-249 # # # Novartis Media Relations E-mail: [email protected] Novartis Investor RelationsCentral investor relations line: +41 61 324 7944 E-mail: [email protected] Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Business Upturn
14 hours ago
- Business Upturn
OWNx Honors U.S. Military with Free Access to Wholesale Gold, Silver, and Platinum
Lawrence, KS , June 01, 2025 (GLOBE NEWSWIRE) — In a bold extension of its mission to make precious metals more accessible to everyone, OWNx today announced an exclusive new initiative: all active-duty military personnel and U.S. military veterans are now eligible to receive the OWNx EDGE™ Membership completely free, gaining access to gold, silver, and platinum at wholesale cost with zero transaction or membership fees. OWNx This unprecedented offer reinforces OWNx's commitment to financial empowerment through transparency, trust, and innovation—values deeply aligned with those of the military community. 'We believe that those who serve our country deserve every opportunity to build and protect their wealth with confidence and integrity,' said Josh McCleary, Co-Founder and COO of OWNx. 'Offering EDGE membership at no cost is our way of saying thank you and ensuring that service members and veterans can access precious metals without unnecessary fees or barriers.' Industry-First Access—Now Free for Military and Veterans The OWNx EDGE™ membership—launched in April 2025—remains the first and only program of its kind in the precious metals industry. Investors typically pay $14.99 monthly or $149 annually for EDGE access. It allows members to buy fractional or whole ounces of physical gold, silver, and platinum at cost, without retail markups or hidden spreads that can range from 5-25% above spot price at traditional dealers. For the military and veteran community, this program is now entirely free for life, with no monthly charges, no commissions, and no administrative fees. Real Investment Impact for Those Who Served The savings from eliminating both membership fees and markups are substantial for military families building wealth. A $25,000 investment in gold with traditional dealers could incur $875 to $2,500 in hidden fees and markups. With free OWNx EDGE for military members, service members and veterans pay nothing beyond the actual cost of the metals, allowing them to put up to $2,400 more into actual precious metals compared to alternatives. Eligible military members and veterans gain: Access to wholesale pricing on gold, silver, and platinum with zero markup No membership fees, account fees, or transaction fees—ever. There is just a small one-time fee of $5 to cover the cost of military verification. Fractional ownership access to low-premium large bars without minimum purchase requirements Secure, insured storage in non-bank depositories in Delaware or Texas at just 0.6% per year (0.5% for IRA holdings) Easy, automated savings tools to build metal holdings over time User-friendly platform with seamless online dashboard and mobile app Full ownership of allocated metals with optional physical delivery (additional shipping costs apply) IRA integration available with OWNx Precious Metals IRA OWNx Built on Trust. Delivered with Purpose. OWNx has long been recognized for its commitment to transparency, client protection, and simplicity—offering a secure way for individuals to diversify into precious metals without hype, pressure, or opaque pricing models. Now, with this new initiative, OWNx further expands its reach to those who have served and sacrificed for the nation. The enrollment process is straightforward: military personnel and veterans can verify their service status at using standard military documentation (DD-214 for veterans, military ID for active duty) to claim their free lifetime EDGE membership. 'With this offer, we're not just waiving fees—we're opening the door to a stronger, fairer financial future,' added McCleary. 'We're honored to support the military community with the tools and transparency they deserve, giving them access to the same institutional pricing that was previously available only to bulk purchasers.' About OWNx Founded in 2008, OWNx is a pioneering platform in the precious metals market, offering secure and innovative solutions for those looking to invest in gold, silver, and platinum. With a focus on technology-driven solutions, OWNx has transformed how individuals access precious metals by providing automatic purchase options, secure storage, and instant trading capabilities, empowering people to diversify their portfolios with confidence. The company's OWNx Precious Metals IRA allows investors to include physical precious metals in their retirement planning while enjoying the benefits of EDGE membership. For more information about us, check out OWNx reviews or Military personnel and veterans can learn more about the free EDGE membership offer at ### Contact Information Josh McClearyCo-Founder and COO [email protected] Lawrence, Kansas
Yahoo
16 hours ago
- Yahoo
OWNx Honors U.S. Military with Free Access to Wholesale Gold, Silver, and Platinum
Company Honors Service Members by Eliminating All Costs for Accessing Gold, Silver, and Platinum at Wholesale Pricing OWNx Honors U.S. Military with Free Access to Wholesale Gold, Silver, and Platinum Lawrence, KS , June 01, 2025 (GLOBE NEWSWIRE) -- In a bold extension of its mission to make precious metals more accessible to everyone, OWNx today announced an exclusive new initiative: all active-duty military personnel and U.S. military veterans are now eligible to receive the OWNx EDGE™ Membership completely free, gaining access to gold, silver, and platinum at wholesale cost with zero transaction or membership fees. OWNx This unprecedented offer reinforces OWNx's commitment to financial empowerment through transparency, trust, and innovation—values deeply aligned with those of the military community. "We believe that those who serve our country deserve every opportunity to build and protect their wealth with confidence and integrity," said Josh McCleary, Co-Founder and COO of OWNx. "Offering EDGE membership at no cost is our way of saying thank you and ensuring that service members and veterans can access precious metals without unnecessary fees or barriers." Industry-First Access—Now Free for Military and Veterans The OWNx EDGE™ membership—launched in April 2025—remains the first and only program of its kind in the precious metals industry. Investors typically pay $14.99 monthly or $149 annually for EDGE access. It allows members to buy fractional or whole ounces of physical gold, silver, and platinum at cost, without retail markups or hidden spreads that can range from 5-25% above spot price at traditional dealers. For the military and veteran community, this program is now entirely free for life, with no monthly charges, no commissions, and no administrative fees. Real Investment Impact for Those Who Served The savings from eliminating both membership fees and markups are substantial for military families building wealth. A $25,000 investment in gold with traditional dealers could incur $875 to $2,500 in hidden fees and markups. With free OWNx EDGE for military members, service members and veterans pay nothing beyond the actual cost of the metals, allowing them to put up to $2,400 more into actual precious metals compared to alternatives. Eligible military members and veterans gain: Access to wholesale pricing on gold, silver, and platinum with zero markup No membership fees, account fees, or transaction fees—ever. There is just a small one-time fee of $5 to cover the cost of military verification. Fractional ownership access to low-premium large bars without minimum purchase requirements Secure, insured storage in non-bank depositories in Delaware or Texas at just 0.6% per year (0.5% for IRA holdings) Easy, automated savings tools to build metal holdings over time User-friendly platform with seamless online dashboard and mobile app Full ownership of allocated metals with optional physical delivery (additional shipping costs apply) IRA integration available with OWNx Precious Metals IRA OWNx Built on Trust. Delivered with Purpose. OWNx has long been recognized for its commitment to transparency, client protection, and simplicity—offering a secure way for individuals to diversify into precious metals without hype, pressure, or opaque pricing models. Now, with this new initiative, OWNx further expands its reach to those who have served and sacrificed for the nation. The enrollment process is straightforward: military personnel and veterans can verify their service status at using standard military documentation (DD-214 for veterans, military ID for active duty) to claim their free lifetime EDGE membership. "With this offer, we're not just waiving fees—we're opening the door to a stronger, fairer financial future," added McCleary. "We're honored to support the military community with the tools and transparency they deserve, giving them access to the same institutional pricing that was previously available only to bulk purchasers." About OWNx Founded in 2008, OWNx is a pioneering platform in the precious metals market, offering secure and innovative solutions for those looking to invest in gold, silver, and platinum. With a focus on technology-driven solutions, OWNx has transformed how individuals access precious metals by providing automatic purchase options, secure storage, and instant trading capabilities, empowering people to diversify their portfolios with confidence. The company's OWNx Precious Metals IRA allows investors to include physical precious metals in their retirement planning while enjoying the benefits of EDGE membership. For more information about us, check out OWNx reviews or Military personnel and veterans can learn more about the free EDGE membership offer at ### Contact Information Josh McCleary Co-Founder and COO service@ Lawrence, Kansas newsroom: Attachment OWNx Honors U.S. Military with Free Access to Wholesale Gold, Silver, and Platinum
